[ 1 ] Lopes C S D, Bernardes C E S, Piedade M F M, et al. A new polymorph of 4 ’ - hydroxyvalerophenone revealed by thermoanalytical and X - ray diffraction studies [ J ] . European Physical JournalSpeccial Topics, 2017, 226(5): 849 - 855. [2]Tao W, Zavalij P Y, Zachariah M R. Crystal structure of a new polymorph of iodic acid, δ-HIO 3, from powder diffraction[J]. Powder Diffraction, 2017, 32(4): 261-264. [3]Sharma K, Kalita A C, Murugavel R. Five different pseudo-polymorphs of 4-aminoarylphosphate: supramolecular aggregation in organophosphates[J]. CrystEngComm, 2017, 19(7): 1058-1070. [4]冒莉,郑启泰,吕扬. 固体药物多晶型的研究进展[J]. 天然产物研究与开发,2005,17(3):371-375. [5]Shi Q, Chen H B, Wang Y N, et al. Recent advances in drug polymorphs: Aspects of pharmaceutical properties and selective crystallization[J]. International Journal of Pharmaceutics, 2022, 611: 121320. [6]Haleblian J, McCrone W. Pharmaceutical applications of polymorphism[J]. Journal of Pharmaceutical Sciences, 1969, 58(8): 911-929. [7]Sarma B, Chen J, Hsi H Y, et al. Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals[J]. Korean Journal of Chemical Engineering, 2011, 28(2): 315-322. [8]Pindelska E, Sokal A, Kolodziejski W. Pharmaceutical cocrystals, salts and polymorphs: Advanced characterization techniques[J]. Advanced Drug Delivery Reviews, 2017, 117: 111-146. [9]Chieng N, Rades T, Aaltonen J. An overview of recent studies on the analysis of pharmaceutical polymorphs[J]. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55(4): 618-644. [10]Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective[J]. Advanced Drug Delivery Reviews, 2004, 56(3): 335-347.
[1]刘松,陈晓丽,吴淑阳,等.盐酸绿卡色林多晶型与稳定性研究[J].浙江理工大学学报,2016,35-36(自科4):625.
LIU Song,CHEN Xiali,WU Shuyang,et al.Research on Polymorphic Form and Stability of Lorcaserin Hydrochloride[J].Journal of Zhejiang Sci-Tech University,2016,35-36(自科二):625.